Stem cells can now give rise to virtually all cell types present in myocardium, offering the prospect of rebuilding the injured heart from its component parts. Our group has recently created human myocardium in the hearts of rats and mice, by transplanting cardiomyocytes derived from human embryonic stem cells (huESCs). Unlike mouse or rat cardiomyocytes, the human cells are highly proliferative, raising the possibility for exponential growth after implantation. Furthermore, newly developed techniques for directed differentiation of cardiomyocytes from hESCs (up to 50% of hESC progeny), coupled with the ability to genetically select human cardiomyocytes at ~98% purity, offer large numbers of highly purified cells for basic and preclinical research. Although promising, several obstacles must be overcome to translate these findings to a therapeutic benefit. In particular, the survival of the cells in the infarcted heart must be improved, their proliferation after implantation needs to be stimulated in a controllable fashion, and we need to prevent scar tissue from blocking their electromechanical integration with host myocardium. Experiments in Aim 1 test the hypothesis that interventions known to block ischemic or apoptotic cell death will reduce death of huESC-derived cardiomyocytes after transplantation. High throughput models will be developed to screen multiple candidates, and the most promising interventions will be tested for their ability to increase formation of human myocardium and restore contractile function in the infarcted rat heart.
Aim 2 builds on our recent finding that huESC-derived cardiomyocyte proliferation requires PI-3 kinase/Akt and can be stimulated by IGF-1. We will develop systems to control human cardiomyocyte proliferation after transplantation using small molecules that activate IGF-1 receptor or FGF receptor signaling pathways in transgenic human cardiomyocytes. We then will determine whether chemically induced signaling through growth factor receptors will increase formation of human myocardium and improve ventricular function post- infarction.
Aim 3 tests the hypothesis that the matricellular protein thrombospondin-2 (Tsp2), known to promote fibrosis and antagonize angiogenesis around biomaterial implants, also promotes fibrosis around cardiomyocyte implants. Peri-implant fibrosis, angiogenesis and graft integration will be measured in Tsp2- null and wild type mice. The ability to control graft cell death, graft cell proliferation and peri-implant fibrosis would substantially advance cell-based cardiac repair. These advances also should be applicable to other diseases treatable by cell therapy, such as diabetes, Parkinson disease and spinal cord injury. In addition to potential therapeutic applications, these studies will provide the first systematic analysis of pathways regulating death and proliferation in human cardiomyocytes. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL084642-01A1
Application #
7211583
Study Section
Myocardial Ischemia and Metabolism Study Section (MIM)
Program Officer
Liang, Isabella Y
Project Start
2007-01-16
Project End
2010-12-31
Budget Start
2007-01-16
Budget End
2007-12-31
Support Year
1
Fiscal Year
2007
Total Cost
$498,102
Indirect Cost
Name
University of Washington
Department
Pathology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Liu, Yen-Wen; Chen, Billy; Yang, Xiulan et al. (2018) Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat Biotechnol 36:597-605
Hofsteen, Peter; Robitaille, Aaron Mark; Strash, Nicholas et al. (2018) ALPK2 Promotes Cardiogenesis in Zebrafish and Human Pluripotent Stem Cells. iScience 2:88-100
Palpant, Nathan J; Wang, Yuliang; Hadland, Brandon et al. (2017) Chromatin and Transcriptional Analysis of Mesoderm Progenitor Cells Identifies HOPX as a Regulator of Primitive Hematopoiesis. Cell Rep 20:1597-1608
Palpant, Nathan J; Pabon, Lil; Friedman, Clayton E et al. (2017) Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells. Nat Protoc 12:15-31
Yang, Xiulan; Murry, Charles E (2017) One Stride Forward: Maturation and Scalable Production of Engineered Human Myocardium. Circulation 135:1848-1850
Kadota, Shin; Pabon, Lil; Reinecke, Hans et al. (2017) In Vivo Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Neonatal and Adult Rat Hearts. Stem Cell Reports 8:278-289
Qin, Wan; Roberts, Meredith A; Qi, Xiaoli et al. (2016) Depth-resolved 3D visualization of coronary microvasculature with optical microangiography. Phys Med Biol 61:7536-7550
Ruan, Jia-Ling; Tulloch, Nathaniel L; Razumova, Maria V et al. (2016) Mechanical Stress Conditioning and Electrical Stimulation Promote Contractility and Force Maturation of Induced Pluripotent Stem Cell-Derived Human Cardiac Tissue. Circulation 134:1557-1567
Roberts, Meredith A; Tran, Dominic; Coulombe, Kareen L K et al. (2016) Stromal Cells in Dense Collagen Promote Cardiomyocyte and Microvascular Patterning in Engineered Human Heart Tissue. Tissue Eng Part A 22:633-44
Thomson, Kassandra S; Odom, Guy L; Murry, Charles E et al. (2016) Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy. JACC Basic Transl Sci 1:666-679

Showing the most recent 10 out of 88 publications